Genetically engineered ERα-positive breast cancer mouse models

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages

  Dabydeen, Sarah A ^a   Furth, Priscilla A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Breast; Carcinoma; Estrogen receptor; Mammary gland; Pathogenesis

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; EFATUTAZONE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; PROLACTIN;

AIB1 GENE; BREAST CANCER; CANCER MODEL; CCDN1 GENE; ESPL1 GENE; ESR1 GENE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; NONHUMAN; ONCOGENE; P53 GENE; PATHOGENESIS; PIK3CA GENE; REVIEW; STAT1 GENE; TGF ALPHA GENE; WNT1 GENE; ANIMAL; BREAST NEOPLASMS; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE;

EID: 84903585223     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0512     Document Type: Review

References (103)

1. Adams JR,XuK, Liu JC, AgamezNM, LochAJ,WongRG,WangW,WrightKL, Lane TF, Zacksenhaus E et al. 2011 Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Research 71 2706-2717. (doi:10.1158/0008-5472. CAN-10-0738)
2. Allred DC, Brown P & Medina D 2004 The origins of estrogen receptor α-positive and estrogen receptor α-negative human breast cancer. Breast Cancer Research 6 240-245. (doi:10.1186/bcr938) (Pubitemid 39440252)
3. Anderson E & Clarke RB 2004 Steroid receptors and cell cycle in normal mammary epithelium. Journal of Mammary Gland Biology and Neoplasia 9 3-13. (doi:10.1023/B:JOMG.0000023584.01750.16) (Pubitemid 39137493)
4. Anderson E, Clarke RB & Howell A 1998 Estrogen responsiveness and control of normal human breast proliferation. Journal of Mammary Gland Biology and Neoplasia 3 23-35. (doi:10.1023/A:1018718117113) (Pubitemid 128513217)
5. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H & Schuler LA 2011 Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Research 13 R11. (doi:10.1186/bcr2819)
6. Ariazi EA, Ariazi JL, Cordera F & Jordan VC 2006 Estrogen receptors as therapeutic targets in breast cancer. Current Topics in Medicinal Chemistry 6 181-202. (doi:10.2174/156802606776173483)
7. Bami S, Lissoni P, Meregalli S, Ardizzoia A, Mengo S, Musco F, Merlini D & Tancini G 1998 Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Tumori 84 45-47. (Pubitemid 28221843)
8. Bhatavdekar JM, Patel DD, Karelia NH, Shah NG, Ghosh N, Vora HH, Suthar TP, Balar DB & Doctor SS 1994 Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer? European Journal of Surgical Oncology 20 118-121. (Pubitemid 24164464)
9. Blanco-Aparicio C, Perez-Gallego L, Pequeno B, Leal JF, Renner O & Carnero A 2007 Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 28 584-594. (doi:10.1093/carcin/bgl190) (Pubitemid 46523354)
10. Booth BW & Smith GH 2007 Roles of transforming growth factor-a in mammary development and disease. Growth Factors 25 227-235. (doi:10.1080/ 08977190701750698)
11. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjold B & Stal O 2013 Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Research and Treatment 137 397-406. (doi:10.1007/s10549-012-2376-y)
12. Bostrom P, Soderstrom M, Palokangas T, Vahlberg T, Collan Y, Carpen O & Hirsimaki P 2009 Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Research Notes 2 140. (doi:10.1186/1756-0500-2-140)
13. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S & Goloubeva O 2005 Therapeutic observations in MCF-7 aromatase xenografts. Clinical Cancer Research 11 884s-888s. (Pubitemid 40111101)
14. Casimiro MC, Wang C, Li Z, Di Sante G, Willmart NE, Addya S, Chen L, Liu Y, Lisanti MP & Pestell RG 2013 Cyclin D1 determines estrogen signaling in the mammary gland in vivo. Molecular Endocrinology 27 1415-1428. (doi:10.1210/me.2013-1065)
15. Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE et al. 2012 STAT1-deficient mice spontaneously develop estrogen receptor a-positive luminal mammary carcinomas. Breast Cancer Research 14 R16. (doi:10.1186/bcr3100)
16. Chan SR, Rickert CG, VermiW, Sheehan KC, Arthur C, Allen JA, White JM, Archambault J, Lonardi S, McDevitt TM et al. 2014 Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERa tumorigenesis. Cell Death and Differentiation 21 234-246. (doi:10.1038/cdd. 2013.116)
17. Chen S & Parmigiani G 2007 Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 25 1329-1333. (doi:10.1200/JCO.2006.09. 1066) (Pubitemid 46706879)
18. Chien CD, Kirilyuk A, Li JV, Zhang W, Lahusen T, Schmidt MO, Oh AS, Wellstein A & Riegel AT 2011 Role of the nuclear receptor coactivatorAIB1-D4 splice variant in the control of gene transcription. Journal of Biological Chemistry 286 26813-26827. (doi:10.1074/jbc.M110.216200)
19. Ciardiello F, KimN,McGeady ML, Liscia DS, Saeki T, Bianco C & Salomon DS 1991 Expression of transforming growth factor a (TGFα) in breast cancer. Annals of Oncology 2 169-182.
20. Clevenger CV, Furth PA, Hankinson SE & Schuler LA 2003 The role of prolactin in mammary carcinoma. Endocrine Reviews 24 1-27. (doi:10.1210/er.2001- 0036) (Pubitemid 36223277)
21. Diaz-Cruz ES & Furth PA 2010 Deregulated estrogen receptor a and p53 heterozygosity collaborate in the development ofmammary hyperplasia. Cancer Research 70 3965-3974. (doi:10.1158/0008-5472.CAN-09-3450)
22. Diaz-Cruz ES, Sugimoto Y, Gallicano GI, BrueggemeierRW& Furth PA 2011 Comparison of increased aromatase versus ERa in the generation of mammary hyperplasia and cancer. Cancer Research 71 5477-5487. (doi:10.1158/0008-5472. CAN-10-4652)
23. van Diest PJ,Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ & Baak JP 1997 Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. American Journal of Pathology 150 705-711. (Pubitemid 27073797)
24. Dowsett M, McGarrick GE, Harris AL, Coombes RC, Smith IE & Jeffcoate SL 1983 Prognostic significance of serumprolactin levels in advanced breast cancer. British Journal of Cancer 47 763-769. (doi:10.1038/bjc.1983.129) (Pubitemid 13053505)
25. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P et al. 2008 Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. Journal of the National Cancer Institute 100 1361-1367. (doi:10.1093/jnci/djn313)
26. Fox EM, Davis RJ & Shupnik MA 2008 ERb in breast cancer-onlooker, passive player, or active protector? Steroids 73 1039-1051. (doi:10.1016/j. steroids.2008.04.006)
27. Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA, Flaws JA & Furth PA 2005 Deregulated estrogen receptor a expression inmammary epithelial cells of transgenicmice results in the development of ductal carcinoma in situ. Cancer Research 65 681-685. (Pubitemid 40216421)
28. Frech MS, Torre KM, Robinson GW & Furth PA 2008 Loss of cyclin D1 in concert with deregulated estrogen receptor a expression induces DNA damage response activation and interrupts mammary gland morphogenesis. Oncogene 27 3186-3193. (doi:10.1038/sj.onc.1210974) (Pubitemid 351693169)
29. Fu M, Wang C, Li Z, Sakamaki T & Pestell RG 2004 Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145 5439-5447. (doi:10.1210/en.2004-0959) (Pubitemid 39564581)
30. Fuchs-Young R, Shirley SH, Lambertz I, Colby JK, Tian J, Johnston D, Gimenez-Conti IB, Donehower LA, Conti CJ & Hursting SD 2011 P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis. Breast Cancer Research and Treatment 130 399-408. (doi:10.1007/s10549-010-1308-y)
31. Furth PA 1997 Conditional control of gene expression in the mammary gland. Journal of Mammary Gland Biology and Neoplasia 2 373-383.(doi:10.1023/A: 1026399329934) (Pubitemid 127718721)
32. Furth PA 2013 STAT signaling in different breast cancer sub-types. Molecular Cell 382 612-615.
33. Gasco M, Shami S & Crook T 2002 The p53 pathway in breast cancer. Breast Cancer Research 4 70-76. (doi:10.1186/bcr426) (Pubitemid 34248123)
34. Geisler J, Smith I & Miller W 2012 Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 131 93-100. (doi:10.1016/j.jsbmb.2011.12.006)
35. Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N et al. 2012 Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement Annals of Oncology 23 2997-3006. (doi:10.1093/annonc/mds586)
36. Gunther EJ, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB & Chodosh LA 2002 A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB Journal 16 283-292. (doi:10.1096/fj.01-0551com)
37. Habashy HO, Powe DG, Abdel-Fatah TM, Gee JM, Nicholson RI, Green AR, Rakha EA & Ellis IO 2012 A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. Histopathology 60 854-863. (doi:10.1111/j.1365-2559.2011.03912.x)
38. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Archives of Pathology & Laboratory Medicine 134 907-922. (doi:10.1043/1543-2165-134.7.e48)
39. Harvey JM, Clark GM, Osborne CK & Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17 1474-1481. (Pubitemid 29220854)
40. Hennighausen L, Wall RJ, Tillmann U, Li M & Furth PA 1995 Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. Journal of Cellular Biochemistry 59 463-472. (doi:10.1002/jcb.240590407) (Pubitemid 26010626)
41. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S et al. 2007 Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biology 8 R76. (doi:10.1186/gb-2007-8-5-r76)
42. Holbro T, Civenni G & Hynes NE 2003 The ErbB receptors and their role in cancer progression. Experimental Cell Research 284 99-110. (doi:10.1016/S0014-4827(02)00099-X) (Pubitemid 36331969)
43. Holliday DL & Speirs V 2011 Choosing the right cell line for breast cancer research. Breast Cancer Research 13 215. (doi:10.1186/bcr2889)
44. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS &Medina D 2000 A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 19 1052-1058. (doi:10.1038/sj.onc.1203270)
45. Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, Rosen EM & Furth PA 2008 Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERa-negative and ERapositive mammary preneoplasia and cancer. Oncogene 27 794-802. (doi:10.1038/sj.onc.1210674) (Pubitemid 351186312)
46. Kirma NB & Tekmal RR 2012 Transgenic mouse models of hormonal mammary carcinogenesis: advantages and limitations. Journal of Steroid Biochemistry and Molecular Biology 131 76-82. (doi:10.1016/j.jsbmb.2011.11.005)
47. Klarenbeek S, van Miltenburg MH & Jonkers J 2013 Genetically engineered mouse models of PI3K signaling in breast cancer. Molecular Oncology 7 146-164. (doi:10.1016/j.molonc.2013.02.003)
48. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D & Hennighausen L 2010 Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 12 899-905.
49. Koromilas AE & Sexl V 2013 The tumor suppressor function of STAT1 in breast cancer. JAK-STAT 2 e23353.
50. Kotta-Loizou I, Giaginis C & Theocharis S 2012 The role of peroxisome proliferator-activated receptor-g in breast cancer. Anti-Cancer Agents in Medicinal Chemistry 12 1025-1044. (doi:10.2174/187152012803529664)
51. Kumar MJ, Ponvijay KS, Nandhini R, Nagarajan RS, Jose J, Srinivas G, Nagarajan P, Venkatesan R, Kumar K & Singh S 2007 A mouse model for luminal epithelial like ER positive subtype of human breast cancer. BMC Cancer 7 180. (doi:10.1186/1471-2407-7-180)
52. Lahusen T, Henke RT, Kagan BL, Wellstein A & Riegel AT 2009 The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Research and Treatment 116 225-237. (doi:10.1007/s10549-009-0405- 2)
53. Lai D, Visser-Grieve S & Yang X 2012 Tumour suppressor genes in chemotherapeutic drug response. Bioscience Reports 32 361-374. (doi:10.1042/BSR20110125)
54. Lange CA & Yee D 2011 Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocrine-Related Cancer 18 C19-C24. (doi:10.1530/ERC-11-0112)
55. Larionov AA & Miller WR 2009 Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncology 5 1415-1428. (doi:10.2217/fon.09.113)
56. Li Y, Hively WP & Varmus HE 2000 Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19 1002-1009. (doi:10.1038/sj.onc.1203273) (Pubitemid 30153783)
57. Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, Yagita H, Lindeman GJ, Smyth GK & Visvader JE 2010 Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Research 12 R21. (doi:10.1186/bcr2560)
58. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH & Lee EY 2004 Somatic mutation of p53 leads to estrogen receptor α-positive and-negative mouse mammary tumors with high frequency of metastasis. Cancer Research 64 3525-3532. (doi:10.1158/0008-5472.CAN-03-3524) (Pubitemid 38657927)
59. Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU & Diehl JA 2008 Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene 27 1231-1242. (doi:10.1038/sj.onc.1210738) (Pubitemid 351294688)
60. Malhotra GK, Zhao X, Band H & Band V 2010 Histological, molecular and functional subtypes of breast cancers. Cancer Biology & Therapy 10 955-960. (doi:10.4161/cbt.10.10.13879)
61. Manavathi B, Dey O, Gajulapalli VN, Bhatia RS, Bugide S & Kumar R 2013 Derailed estrogen signaling and breast cancer: an authentic couple. Endocrine Reviews 34 1-32. (doi:10.1210/er.2011-1057)
62. Medina D, Kittrell FS, Shepard A, Stephens LC, Jiang C, Lu J, Allred DC, McCarthy M & Ullrich RL 2002 Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB Journal 16 881-883.
63. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM & Lydon J 2003 Hormone dependence in premalignant mammary progression. Cancer Research 63 1067-1072. (Pubitemid 36278440)
64. Miermont AM, Parrish AR & Furth PA 2010 Role of ERa in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis 31 1124-1131. (doi:10.1093/carcin/bgq048)
65. Miermont AM, CabreraMC, Frech SM, Nakles RE, Diaz-Cruz ES, Shiffert MT & Furth PA 2012 Association of over-expressed estrogen receptor a with development of tamoxifen resistant hyperplasia and adenocarcinomas in genetically engineered mice. Anatomy & Physiology (Supplement 12) pii001.
66. Mohibi S, Mirza S, Band H & Band V 2011 Mouse models of estrogen receptor-positive breast cancer. Journal of Carcinogenesis 10 35. (doi:10.4103/1477-3163.91116)
67. MukherjeeM, Ge G, Zhang N, Edwards DG, Sumazin P, Sharan SK, Rao PH & Medina D 2013 MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor a (ERa)-positive mammary adenocarcinomas. Oncogene [in press]. (doi:10.1038/onc.2013.493)
68. Nakles RE, Shiffert MT, Diaz-Cruz ES, Cabrera MC, Alotaiby M, Miermont AM, Riegel AT & Furth PA 2011 Altered AIB1 or AIB1D3 expression impacts ERa effects on mammary gland stromal and epithelial content. Molecular Endocrinology 25 549-563. (doi:10.1210/me.2010-0114)
69. Nakles RE, Kallakury BV & Furth PA 2013 The PPARg agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency. American Journal of Pathology 182 1976-1985. (doi:10.1016/j.ajpath.2013.02.006)
70. Noguchi S, Motomura K, Inaji H, Imaoka S & Koyama H 1993 Downregulation of transforming growth factor-a by tamoxifen in human breast cancer. Cancer 72 131-136. (doi:10.1002/1097-0142(19930701)72:1〈131::AID- CNCR2820720125〉.0.CO;2-Z) (Pubitemid 23182062)
71. O'Leary KA, Jallow F, Rugowski DE, Sullivan R, Sinkevicius KW, Greene GL & Schuler LA 2013 Prolactin activates ERa in the absence of ligand in female mammary development and carcinogenesis in vivo. Endocrinology 154 4483-4492. (doi:10.1210/en.2013-1533)
72. Parmar H & Cunha GR 2004 Epithelial-stromal interactions in the mouse and human mammary gland in vivo. Endocrine-Related Cancer 11 437-458. (doi:10.1677/erc.1.00659) (Pubitemid 39331276)
73. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM et al. 2013 Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biology 14 R125. (doi:10.1186/gb-2013-14-11-r125)
74. Prefontaine GG, Walther R, GiffinW, Lemieux ME, Pope L & Hache RJ 1999 Selective binding of steroid hormone receptors to octamer transcription factors determines transcriptional synergism at the mouse mammary tumor virus promoter. Journal of Biological Chemistry 274 26713-26719. (doi:10.1074/jbc.274. 38.26713)
75. Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E & Cardiff RD 2009 Mammary tumor phenotypes in wildtype aging female FVB/N mice with pituitary prolactinomas. Veterinary Pathology 46 736-745. (doi:10.1354/vp.08-VP-0280-R-FL)
76. Renoir JM, Marsaud V & Lazennec G 2013 Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochemical Pharmacology 85 449-465. (doi:10.1016/j.bcp.2012.10.018)
77. Roepstorff K, Grovdal L, Grandal M, Lerdrup M & van Deurs B 2008 Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochemistry and Cell Biology 129 563-578. (doi:10.1007/s00418-008-0401-3)
78. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP & Schuler LA 2003 Prolactin induces ERα-positive and ERα-negative mammary cancer in transgenic mice. Oncogene 22 4664-4674. (doi:10.1038/sj.onc.1206619) (Pubitemid 36976441)
79. Rose-Hellekant TA, Schroeder MD, Brockman JL, Zhdankin O, Bolstad R, Chen KS, Gould MN, Schuler LA & Sandgren EP 2007 Estrogen receptorpositive mammary tumorigenesis in TGFα transgenic mice progresses with progesterone receptor loss. Oncogene 26 5238-5246. (doi:10.1038/sj.onc.1210340) (Pubitemid 47237633)
80. Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ & Fuchs-Young R 2009 Transcriptional regulation of estrogen receptor-a by p53 in human breast cancer cells. Cancer Research 69 3405-3414. (doi:10.1158/0008-5472.CAN-08-3628)
81. Shockett P, Difilippantonio M, Hellman N & Schatz DG 1995 A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. PNAS 92 6522-6526. (doi:10.1073/pnas.92. 14.6522)
82. Shull JD 2007 The rat oncogenome: comparative genetics and genomics of rat models of mammary carcinogenesis. Breast Disease 28 69-86. (Pubitemid 350187027)
83. Sutherland RL & Musgrove EA 2002 Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Research 4 14-17. (doi:10.1186/bcr411) (Pubitemid 34097551)
84. Tekmal RR, Nair HB, Perla RP & Kirma N 2007 HER-2/neu x aromatase double transgenic mice model: the effects of aromatase overexpression on mammary tumorigenesis. Journal of Steroid Biochemistry and Molecular Biology 106 111-118. (doi:10.1016/j.jsbmb.2007.05.009) (Pubitemid 47362657)
85. Tilli MT, Frech MS, Steed ME, Hruska KS, Johnson MD, Flaws JA & Furth PA 2003 Introduction of estrogen receptor-a into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. American Journal of Pathology 163 1713-1719. (doi:10.1016/S0002-9440(10)63529-8) (Pubitemid 37310001)
86. TomicD, FrechMS, Babus JK, Symonds D, Furth PA, Koos RD&Flaws JA 2007 Effects of ERa overexpression on female reproduction in mice. Reproductive Toxicology 23 317-325. (doi:10.1016/j.reprotox.2006.08.004) (Pubitemid 46602922)
87. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, SellersWR& BrownM2004 High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6 263-274. (doi:10.1016/j.ccr.2004.06.027) (Pubitemid 39222039)
88. Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA & Hankinson SE 2013 A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Research 73 4810-4819. (doi:10.1158/0008-5472.CAN-13-0665)
89. Uji K, Naoi Y, Kagara N, Shimoda M, Shimomura A, Maruyama N, Shimazu K, Kim SJ & Noguchi S 2013 Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer. Cancer Letters 342 19-26. (doi:10.1016/j. canlet.2013.08.028)
90. Ursini-Siegel J, Schade B, Cardiff RD & Muller WJ 2007 Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Reviews. Cancer 7 389-397. (doi:10.1038/nrc2127) (Pubitemid 46652484)
91. Visvader JE 2009 Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes and Development 23 2563-2577. (doi:10.1101/gad. 1849509)
92. Wagner KU, Wall RJ, St-Onge L, Gruss P,Wynshaw-Boris A, Garrett L, Li M, Furth PA & Hennighausen L 1997 Cre-mediated gene deletion in the mammary gland. Nucleic Acids Research 25 4323-4330. (doi:10.1093/nar/25.21.4323) (Pubitemid 27485212)
93. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R & Hennighausen L 2001 Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Research 10 545-553. (doi:10.1023/A:1013063514007) (Pubitemid 34043179)
94. Walerych D, NapoliM, Collavin L & Del Sal G 2012 The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33 2007-2017. (doi:10.1093/carcin/bgs232)
95. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A & Schmidt EV 1994 Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369 669-671. (doi:10.1038/369669a0) (Pubitemid 24199473)
96. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T et al. 2005 Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Research 65 8166-8173. (doi:10.1158/0008-5472.CAN-05-1650) (Pubitemid 41330580)
97. Wong C & Chen S 2012 The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance. Journal of Steroid Biochemistry and Molecular Biology 131 83-92. (doi:10.1016/j.jsbmb.2011.12.005)
98. Xu J, Wu RC & O'Malley BW 2009 Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nature Reviews. Cancer 9 615-630. (doi:10.1038/nrc2695)
99. Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y & Yamashita H 2014 p53 accumulation is a strong predictor of recurrence in ER-positive breast cancer patients treated with aromatase inhibitors. Cancer Science 105 81-88. (doi:10.1111/cas.12302)
100. Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, Oga A, Nagashima Y & Sasaki K 2012 Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Research Notes 5 376. (doi:10.1186/1756-0500-5-376)
101. Yin Y, Yuan H, Zeng X, Kopelovich L & Glazer RI 2009 Inhibition of peroxisome proliferator-activated receptor g increases estrogen receptor-dependent tumor specification. Cancer Research 69 687-694. (doi:10.1158/0008-5472.CAN-08-2446)
102. Yoshidome K, Shibata MA, Couldrey C, Korach KS & Green JE 2000 Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptora expression during tumor progression. Cancer Research 60 6901-6910. (Pubitemid 32059162)
103. Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R & Li Y 2005 Estrogen receptor positivity in mammary tumors ofWnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene 24 4220-4231. (doi:10.1038/sj.onc.1208597) (Pubitemid 40961776)